Literature DB >> 30771426

Caveolin-1 enhances metastasis formation in a human model of embryonal rhabdomyosarcoma through Erk signaling cooperation.

Silvia Codenotti1, Fiorella Faggi1, Roberto Ronca1, Paola Chiodelli1, Elisabetta Grillo1, Michele Guescini2, Francesca Megiorni3, Francesco Marampon4, Alessandro Fanzani5.   

Abstract

Rhabdomyosarcoma (RMS) is a pediatric soft tissue tumor classified in two major subtypes namely embryonal and alveolar, which have distinctive histopathological and genetic signatures and worse outcomes in the presence of metastases. Here, in order to evaluate the role of Caveolin-1 (Cav-1) in embryonal RMS dissemination, we employed an experimental in vivo metastasis assay using immunodeficient NOD/SCID mice. We found that the intravenous injection of human RD cells engineered for Cav-1 overexpression promoted the formation of lung metastases compared to parental cells. The arisen metastases were isolated and cultured in vitro to establish two derivative lines that showed greater metastatic capacity, as detected by performing in vivo metastasis and tumor spheroid invasion assays. Compared to parental cells, all metastatic lines were characterized by an increase in cell proliferation, migration and invasiveness that were downregulated by synthetic inhibition of Erk pathway. The metastatic cells showed a marked cell apoptosis induced by nutrient deprivation and consistent loss of differentiation characterized by depletion of MyoD and Myogenin factors. Furthermore, they showed marked changes in cell size, a re-organization of the three-dimensional cytoskeleton characterized by an increased actin stress fiber content, and increased adhesion and angiogenic properties. Collectively, these data provide new insights into Cav-1-driven metastatic process of embryonal RMS through cooperation of the Erk signaling pathway. Furthermore, our derivative metastatic lines represent useful tools for identifying genes or molecular pathways that regulate the metastatic progression of embryonal RMS.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Caveolin-1; ERK pathway; Metastasis; Rhabdomyosarcoma

Year:  2019        PMID: 30771426     DOI: 10.1016/j.canlet.2019.02.013

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

Review 1.  Cell Intrinsic and Extrinsic Mechanisms of Caveolin-1-Enhanced Metastasis.

Authors:  America Campos; Renato Burgos-Ravanal; María Fernanda González; Ricardo Huilcaman; Lorena Lobos González; Andrew Frederick Geoffery Quest
Journal:  Biomolecules       Date:  2019-07-29

2.  Clinicopathological and prognostic significance of caveolin-1 and ATG4C expression in the epithelial ovarian cancer.

Authors:  Yuyang Zeng; Mengxi Chen; Sridha Ganesh; Shunze Hu; Honglei Chen
Journal:  PLoS One       Date:  2020-05-13       Impact factor: 3.240

Review 3.  FAK Signaling in Rhabdomyosarcoma.

Authors:  Clara Perrone; Silvia Pomella; Matteo Cassandri; Maria Rita Braghini; Michele Pezzella; Franco Locatelli; Rossella Rota
Journal:  Int J Mol Sci       Date:  2020-11-10       Impact factor: 5.923

Review 4.  Radioresistance in rhabdomyosarcomas: Much more than a question of dose.

Authors:  Simona Camero; Matteo Cassandri; Silvia Pomella; Luisa Milazzo; Francesca Vulcano; Antonella Porrazzo; Giovanni Barillari; Cinzia Marchese; Silvia Codenotti; Miriam Tomaciello; Rossella Rota; Alessandro Fanzani; Francesca Megiorni; Francesco Marampon
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

Review 5.  Modeling neoplastic disease with spheroids and organoids.

Authors:  Michele Zanoni; Michela Cortesi; Alice Zamagni; Chiara Arienti; Sara Pignatta; Anna Tesei
Journal:  J Hematol Oncol       Date:  2020-07-16       Impact factor: 17.388

6.  Cav-1 Ablation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Growth through Nrf2-Induced shh Signaling.

Authors:  Shan Shao; Tao Qin; Weikun Qian; Xuqi Li; Wei Li; Liang Han; Dong Zhang; Zheng Wang; Qingyong Ma; Zheng Wu; Erxi Wu; Jianjun Lei
Journal:  Oxid Med Cell Longev       Date:  2020-04-20       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.